Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
6(75.0%)
Phase 2
2(25.0%)
8Total
Phase 1(6)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06788756Phase 2Recruiting

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Role: lead

NCT05879250Phase 2Recruiting

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Role: collaborator

NCT05319587Phase 1Completed

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Role: lead

NCT04887298Phase 1Completed

Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

Role: lead

NCT05195723Phase 1Completed

Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers

Role: lead

NCT03388749Phase 1Completed

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Role: lead

NCT03315039Phase 1Completed

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Role: lead

NCT04702503Phase 1Completed

Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)

Role: lead

All 8 trials loaded